Changeflow GovPing Trade & Sanctions NHLBI Participation in NIH Exploratory/Developm...
Routine Notice Amended Final

NHLBI Participation in NIH Exploratory/Developmental Research Project Grant (R21)

Favicon for grants.nih.gov NIH Guide Funding Opportunities
Published May 8th, 2026
Detected March 26th, 2026
Email

Summary

The National Heart, Lung, and Blood Institute (NHLBI) announced its participation in the NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) program, PA-25-304. This participation is effective for application due dates on or after May 8, 2026.

What changed

The National Heart, Lung, and Blood Institute (NHLBI) has issued a notice to inform potential applicants of its participation in the NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) program, identified as PA-25-304. This participation means that applications submitted to PA-25-304 for due dates on or after May 8, 2026, will be subject to NHLBI's mission and funding priorities.

Researchers interested in applying for this R21 grant should ensure their proposed projects align with the NHLBI's research areas. The effective date for NHLBI's participation is May 8, 2026, which is the first application due date for which this participation will be in effect. No immediate action is required for entities not planning to apply for this specific grant.

What to do next

  1. Review NHLBI's participation in PA-25-304 for research alignment.
  2. Note the effective date of May 8, 2026, for applications.

Source document (simplified)

Notice of NHLBI Participation in PA-25-304 "NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)" Notice Number: NOT-HL-26-003

Key Dates

Release Date: March 26, 2026

Related Announcements

  • December 18, 2024 - NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed). See PA-25-304.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) will participate in PA-25-304, “NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed" effective for application due dates on or after May 8, 2026.

The following text in bold and italics has been added to reflect NHLBI's participation:

Part 1. Overview Information

Components of Participating Organizations

NATIONAL INSTITUTES OF HEALTH (NIH)

National Eye Institute (NEI)

National Human Genome Research Institute (NHGRI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

National Library of Medicine (NLM)

National Center for Complementary and Integrative Health (NCCIH)

National Institute on Minority Health and Health Disparities (NIMHD), June 26, 2025 - Participation added (NOT-MD-25-010)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), August 12, 2025 - Participation added (NOT-AR-25-019)

National Cancer Institute (NCI), September 2, 2025 - Participation added (NOT-CA-25-118)

National Heart, Lung, and Blood Institute **** ( NHLBI )

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Data Science Strategy (ODSS)

Assistance Listing Number(s)

93.865, 93.173, 93.867, 93.879, 93.121, 93.286, 93.273, 93.855, 93.242, 93.172, 93.279, 93.361, 93.866, 93.113, 93.143, 93.213, 93.310, 93.307, 93.846, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.840, 93.233

Inquiries

Please direct all inquiries regarding this notice to:

National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: PA-25-304

Office of Grants Management
National Heart, Lung, and Blood Institute (NHLBI)
Email: [email protected]
Subject: PA-25-304

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices Department of Health
and Human Services (HHS) NIH... Turning Discovery Into Health ®

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
NHLBI
Published
May 8th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NOT-HL-26-003

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Research Funding
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Research & Development
Topics
Research Funding Grant Programs

Get Trade & Sanctions alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when NIH Guide Funding Opportunities publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.